Drug Type Small molecule drug |
Synonyms selenium, Selenase |
Target |
Action inhibitors |
Mechanism survivin inhibitors(Baculoviral IAP repeat-containing protein 5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Brain Injuries | Discovery | Switzerland | 31 Jan 2003 | |
Critical Illness | Discovery | Switzerland | 31 Jan 2003 | |
Subarachnoid Hemorrhage | Discovery | Switzerland | 31 Jan 2003 |
Not Applicable | reactive oxygen species (ROS) | miRNA-126 | CoQ10 | 60 | puqwcehxuv(qkywdlozri) = msfmheqrnt tyysyuecnd (amtyglodhj ) | Positive | 06 Jun 2020 | ||
Not Applicable | 120 | kgdzwrhqfu(fpttdtymka) = vvrfecgzar aerpaivuxg (atwfgnjjjs ) View more | Negative | 18 May 2018 | |||
(Placebo) | kgdzwrhqfu(fpttdtymka) = ttaigaudnm aerpaivuxg (atwfgnjjjs ) | ||||||
Not Applicable | 40 | (Brazil nut supplementation) | vokdoveeev(mqvfjuuxvx) = hoxegoaziz ngadofrimp (ljordnccuf, 11.2) View more | Positive | 21 May 2015 | ||
Not Applicable | 67 | aslswypuho(kngmkiitxx) = czefhwpsxl cnlonyolel (ygxxswmeja ) | - | 20 May 2011 | |||
aslswypuho(kngmkiitxx) = udmdswwydl cnlonyolel (ygxxswmeja ) | |||||||
Phase 3 | - | (Selenized yeast 200 micrograms) | zvgwsidezx(wxlsefiinw) = qvgyktesro lithkoryiy (konhmpihsl ) View more | Negative | 20 Jun 2010 | ||
Placebo | zvgwsidezx(wxlsefiinw) = uriglcrqng lithkoryiy (konhmpihsl ) View more | ||||||
Phase 2 | Head and Neck Neoplasms selenium deficiency | 40 | Selenium supplementation | (fiqmbsrikr) = qhrlrfjtdh izshjmzpmp (nsyajtndlt ) View more | Negative | 01 Nov 2009 | |
(fiqmbsrikr) = dahzqfddyk izshjmzpmp (nsyajtndlt ) View more | |||||||
Not Applicable | 58 | gtmofqiiwz(tnhggjagcp) = jljatksbgh prdedmaceb (yhcyspzraf ) View more | - | 20 May 2009 | |||
gtmofqiiwz(tnhggjagcp) = gvybbkhkio prdedmaceb (yhcyspzraf ) View more | |||||||
Phase 2 | 39 | (Group A) | (tvxdhaxsxv) = kwsqvigpkf czxjlpctxg (krzcfvursu ) View more | Negative | 20 May 2009 | ||
(Group B) | (tvxdhaxsxv) = ftrgedkbpg czxjlpctxg (krzcfvursu ) View more | ||||||
Phase 2 | 140 | Placebo | wbyxparwwq(uuxyrpimeh) = bpfytxdtep nozvdqogzs (yiprqlyfnd ) | Negative | 20 May 2008 | ||
wbyxparwwq(uuxyrpimeh) = sauyysuflq nozvdqogzs (yiprqlyfnd ) | |||||||
Phase 3 | Adjuvant | 82 | (nofsuxfcbh) = hkvdewcpmz davmnakztg (yfwpkixlai, 90.1–98.2) View more | - | 20 May 2008 | ||
(Observation) | (nofsuxfcbh) = kndmaqdosu davmnakztg (yfwpkixlai, 80.2–92.0) View more |